FT : Alzheimer’s drug Leqembi falls short of blockbuster status in faltering US Alzheimer’s drug Leqembi falls short of blockbuster status in faltering US rolloutHigh costs and concerns over efficacy and side effects limit uptake of first treatment as another nears approval Download Alzheimer_s_drug_Leqembi_falls_short_of_blockbuster_status_in_faltering_US_rollout.pdf